Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?

ABSTRACT Purpose: To evaluate the role of ARDT after surgical resection of ACC. Materials and Methods: Records of patients from our institutional ACC database were retrospectively assessed. A paired comparison analysis was used to evaluate the oncological outcomes between patients treated with surgery followed by ARDT or surgery only (control). The endpoints were LRFS, RFS, and OS. A systematic review of the literature and meta-analysis was also performed to evaluate local recurrence of ACC when ARDT was used. Results: Ten patients were included in each Group. The median follow-up times were 32 months and 35 months for the ARDT and control Groups, respectively. The results for LRFS (p=0.11), RFS (p=0.92), and OS (p=0.47) were similar among subsets. The mean time to present with local recurrence was significantly longer in the ARDT group compared with the control Group (419±206 days vs. 181±86 days, respectively; p=0.03). ARDT was well tolerated by the patients; there were no reports of late toxicity. The meta-analysis, which included four retrospective series, revealed that ARDT had a protective effect on LRFS (HR=0.4; CI=0.17-0.94). Conclusions: ARDT may reduce the chance and prolong the time to ACC local recurrence. However, there were no benefits for disease recurrence control or overall survival for patients who underwent this complementary therapy.

Saved in:
Bibliographic Details
Main Authors: Srougi,Victor, Bessa Junior,Jose, Tanno,Fabio Y., Ferreira,Amanda M., Hoff,Ana O., Bezerra,João E., Almeida,Cristiane M., Almeida,Madson Q., Mendonça,Berenice B., Nahas,William C., Chambô,Jose L., Srougi,Miguel, Fragoso,Maria C. B. V.
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Urologia 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382017000500841
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1677-55382017000500841
record_format ojs
spelling oai:scielo:S1677-553820170005008412017-11-17Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?Srougi,VictorBessa Junior,JoseTanno,Fabio Y.Ferreira,Amanda M.Hoff,Ana O.Bezerra,João E.Almeida,Cristiane M.Almeida,Madson Q.Mendonça,Berenice B.Nahas,William C.Chambô,Jose L.Srougi,MiguelFragoso,Maria C. B. V. Adrenocortical Carcinoma Radiotherapy Adjuvant Therapeutics ABSTRACT Purpose: To evaluate the role of ARDT after surgical resection of ACC. Materials and Methods: Records of patients from our institutional ACC database were retrospectively assessed. A paired comparison analysis was used to evaluate the oncological outcomes between patients treated with surgery followed by ARDT or surgery only (control). The endpoints were LRFS, RFS, and OS. A systematic review of the literature and meta-analysis was also performed to evaluate local recurrence of ACC when ARDT was used. Results: Ten patients were included in each Group. The median follow-up times were 32 months and 35 months for the ARDT and control Groups, respectively. The results for LRFS (p=0.11), RFS (p=0.92), and OS (p=0.47) were similar among subsets. The mean time to present with local recurrence was significantly longer in the ARDT group compared with the control Group (419±206 days vs. 181±86 days, respectively; p=0.03). ARDT was well tolerated by the patients; there were no reports of late toxicity. The meta-analysis, which included four retrospective series, revealed that ARDT had a protective effect on LRFS (HR=0.4; CI=0.17-0.94). Conclusions: ARDT may reduce the chance and prolong the time to ACC local recurrence. However, there were no benefits for disease recurrence control or overall survival for patients who underwent this complementary therapy.info:eu-repo/semantics/openAccessSociedade Brasileira de UrologiaInternational braz j urol v.43 n.5 20172017-10-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382017000500841en10.1590/s1677-5538.ibju.2017.0095
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Srougi,Victor
Bessa Junior,Jose
Tanno,Fabio Y.
Ferreira,Amanda M.
Hoff,Ana O.
Bezerra,João E.
Almeida,Cristiane M.
Almeida,Madson Q.
Mendonça,Berenice B.
Nahas,William C.
Chambô,Jose L.
Srougi,Miguel
Fragoso,Maria C. B. V.
spellingShingle Srougi,Victor
Bessa Junior,Jose
Tanno,Fabio Y.
Ferreira,Amanda M.
Hoff,Ana O.
Bezerra,João E.
Almeida,Cristiane M.
Almeida,Madson Q.
Mendonça,Berenice B.
Nahas,William C.
Chambô,Jose L.
Srougi,Miguel
Fragoso,Maria C. B. V.
Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
author_facet Srougi,Victor
Bessa Junior,Jose
Tanno,Fabio Y.
Ferreira,Amanda M.
Hoff,Ana O.
Bezerra,João E.
Almeida,Cristiane M.
Almeida,Madson Q.
Mendonça,Berenice B.
Nahas,William C.
Chambô,Jose L.
Srougi,Miguel
Fragoso,Maria C. B. V.
author_sort Srougi,Victor
title Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
title_short Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
title_full Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
title_fullStr Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
title_full_unstemmed Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
title_sort adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?
description ABSTRACT Purpose: To evaluate the role of ARDT after surgical resection of ACC. Materials and Methods: Records of patients from our institutional ACC database were retrospectively assessed. A paired comparison analysis was used to evaluate the oncological outcomes between patients treated with surgery followed by ARDT or surgery only (control). The endpoints were LRFS, RFS, and OS. A systematic review of the literature and meta-analysis was also performed to evaluate local recurrence of ACC when ARDT was used. Results: Ten patients were included in each Group. The median follow-up times were 32 months and 35 months for the ARDT and control Groups, respectively. The results for LRFS (p=0.11), RFS (p=0.92), and OS (p=0.47) were similar among subsets. The mean time to present with local recurrence was significantly longer in the ARDT group compared with the control Group (419±206 days vs. 181±86 days, respectively; p=0.03). ARDT was well tolerated by the patients; there were no reports of late toxicity. The meta-analysis, which included four retrospective series, revealed that ARDT had a protective effect on LRFS (HR=0.4; CI=0.17-0.94). Conclusions: ARDT may reduce the chance and prolong the time to ACC local recurrence. However, there were no benefits for disease recurrence control or overall survival for patients who underwent this complementary therapy.
publisher Sociedade Brasileira de Urologia
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382017000500841
work_keys_str_mv AT srougivictor adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT bessajuniorjose adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT tannofabioy adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT ferreiraamandam adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT hoffanao adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT bezerrajoaoe adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT almeidacristianem adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT almeidamadsonq adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT mendoncabereniceb adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT nahaswilliamc adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT chambojosel adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT srougimiguel adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
AT fragosomariacbv adjuvantradiotherapyfortheprimarytreatmentofadrenocorticalcarcinomaareweofferingthebest
_version_ 1756428235419156480